Tmunity Therapeutics

Tmunity Announces First Patient Dosed in Phase 1 Clinical Trial with CART-TnMUC1

Retrieved on: 
Wednesday, January 15, 2020
Research, Technology, FDA, Other Technology, Clinical trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, MUC1, Branches of biology, Mucin, Biology, Pankomab, CA-125, the CART-TnMUC1-01 Phase 1 Trial, Tmunity Therapeutics

The MUC1 glycoprotein is a transmembrane epithelial mucin normally expressed on the apical surface of most simple glandular epithelial cells.

Key Points: 
  • The MUC1 glycoprotein is a transmembrane epithelial mucin normally expressed on the apical surface of most simple glandular epithelial cells.
  • In tumors that arise from these cells, an alternate form of MUC1 is frequently overexpressed on the cancer cell surface.
  • This clinical trial marks the third program from our portfolio to enter the clinical testing phase since our company was founded in 2015.
  • The primary objective of the trial is to establish safety and the recommended Phase 2 dose of CART-TnMUC1 that can be administered with lymphodepletion.

Tmunity and Oncora Medical Partner to Advance the Use of Real-World Data to Accelerate the Availability of CAR-T Therapies for Cancer Patients

Retrieved on: 
Monday, November 4, 2019
Biotechnology, Pharmaceutical, Health, Oncology, Health, Clinical research, Clinical pharmacology, Clinical trial, Design of experiments, Pharmaceutical industry, Medical research, Tmunity Therapeutics, Oncora Medical

Together, this collaboration has the potential to innovate the way clinical trials for cell therapy are executed to bring treatments to patients more efficiently.

Key Points: 
  • Together, this collaboration has the potential to innovate the way clinical trials for cell therapy are executed to bring treatments to patients more efficiently.
  • Tmunity will leverage Oncoras data and analytics capabilities to refine, customize and validate a real-world evidence strategy.
  • Partnering with Oncora Medical to utilize real-world data in clinical development puts Tmunity at the forefront of innovation.
  • For more information on how Oncora is fighting cancer with data, visit oncoramedical.com and connect with us on social media at @oncoramed and LinkedIn .

Be The Match BioTherapies® and Tmunity Announce Collaboration to Support Clinical Trials of Next-Generation Immunotherapies

Retrieved on: 
Tuesday, July 9, 2019
Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Articles, Health sciences, Cancer treatments, Virotherapy, Immunotherapy, Therapy, Gene therapy, Be The Match BioTherapies, Tmunity Therapeutics

These personalized next-generation immunotherapies for cancer are advancing through preclinical and clinical testing.

Key Points: 
  • These personalized next-generation immunotherapies for cancer are advancing through preclinical and clinical testing.
  • We look forward to working together to deliver powerful new options for patients and to bring about the future of cell therapy.
  • Be The Match BioTherapies will support Tmunitys ongoing work to advance T cell immunotherapies.
  • Be The Match BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain.